US · ENSC · BIOTECHNOLOGY
Ensysce Biosciences, Inc. (ENSC) intrinsic value and stock valuation
$0.36as of 2026-11-21 · Mkt cap 4.83M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ensysce Biosciences, Inc. DCF and intrinsic value
InvestorsCraft values ENSC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENSC’s statements →
Ensysce Biosciences, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M |
| Operating income | -$-10.24M | -$-6.73M | -$-10.72M | -$-24.22M | -$-19.87M |
| Net income | -$-10.18M | -$-7.99M | -$-10.61M | -$-24.17M | -$-29.08M |
| EPSd | -$-398.12K | -$-4.57M | -$-4.69M | -$-134.28M | -$-363.5M |
| Operating cash flow | -$-7.81T | -$-7.5T | -$-10.78M | -$-17.89M | -$-8.24M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-7.81T | -$-7.5T | -$-10.78M | -$-17.89M | -$-8.24M |
| Total assets | $7.45M | $5.6M | $2.71M | $5.89M | $16.4M |
| Total debt | $306.7B | $300K | $850K | $4.43M | $17.2M |
| Net debt | $306.7B | -$-3.2M | -$-270K | $1.29M | $4.95M |
| Total equity | $2.88M | $3.38M | -$-650K | -$-4.03M | -$-8.16M |
| Cash and short-term investments | $4.31M | $3.5M | $1.12M | $3.15M | $12.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M |
| Cost of revenue | $10.4M | $7.22M | $7.59M | $19.8M | $0.00 |
| Gross profit | -$-5.31M | -$-2.01M | -$-5.36M | -$-17.31M | $3.53M |
| Research and development expenses | $10.4M | $7.22M | $7.59M | $19.8M | $4.69M |
| Selling, general and administrative expenses | $4.93M | $4.72M | $5.36M | $6.91M | $18.7M |
| Other expenses | -$-10.38M | -$-7.22M | -$-7.59M | -$-19.84M | -$-3.53M |
| Operating expenses | $4.93M | $4.72M | $5.36M | $6.91M | $23.4M |
| Cost and expenses | $15.3M | $11.9M | $13M | $26.8M | $23.4M |
| Interest income | $0.00 | $0.00 | $0.00 | $1.25M | $3.21M |
| Interest expense | $20K | $1.29M | $350K | $110K | $1.29M |
| Depreciation and amortization | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Ebitda | -$-10.15M | -$-6.73M | -$-10.72M | -$-24.22M | -$-25.93M |
| Operating income | -$-10.24M | -$-6.73M | -$-10.72M | -$-24.22M | -$-19.87M |
| Total other income/expenses, net | $60K | -$-1.26M | $90K | $10K | -$-9.28M |
| Income before tax | -$-10.18M | -$-7.99M | -$-10.63M | -$-24.21M | -$-29.15M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-10.18M | -$-7.99M | -$-10.61M | -$-24.17M | -$-29.08M |
| Weighted average shares outstanding | $2.56M | $1.75M | $2.26M | $180K | $80K |
| Weighted average diluted shares outstanding | $25.6M | $1.75M | $2.26M | $180K | $80K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.31M | $3.5M | $1.12M | $3.15M | $12.3M |
| Net receivables | $420K | $120K | $100K | $280K | $440K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-440K |
| Total current assets | $7.24M | $5.34M | $2.29M | $5.3M | $15.7M |
| Property, plant and equipment, net | $124.1B | $0.00 | $0.00 | $0.00 | $24.7B |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $210K | $250K | $420K | $590K | $750K |
| Total assets | $7.45M | $5.6M | $2.71M | $5.89M | $16.4M |
| Accounts payable | $3.27M | $1.36M | $1.94M | $2.94M | $300K |
| Short-term debt | $306.7B | $300K | $850K | $4.29M | $12.8M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $4.57M | $2.21M | $3.33M | $9.46M | $16.5M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $140K | $4.44M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $10K | $30K | $450K | $8.09M |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $30K | $20K |
| Total liabilities | $4.57M | $2.22M | $3.36M | $9.91M | $24.6M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-139.72M | -$-129.54M | -$-121.56M | -$-110.93M | -$-85.85M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $2.88M | $3.38M | -$-650K | -$-4.03M | -$-8.16M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $306.7B | $300K | $850K | $4.43M | $17.2M |
| Net debt | $306.7B | -$-3.2M | -$-270K | $1.29M | $4.95M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-10.18T | -$-7.99M | -$-10.63M | -$-24.21M | -$-29.15M |
| Depreciation and amortization | $6.53B | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $668.7B | $110.7B | $880K | $1.07M | $120K |
| Change in working capital | $1.52M | -$-850K | -$-950K | $5.48M | -$-1.3M |
| Accounts receivable | -$-300K | -$-30K | $180K | $160K | -$-440K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $1.82M | -$-580K | -$-1.23M | $2.64M | -$-1.42M |
| Net cash provided by operating activities | -$-7.81T | -$-7.5T | -$-10.78M | -$-17.89M | -$-8.24M |
| Investments in property, plant and equipment | -$-120K | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-123.64B | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock issued | $5.87M | $1.67M | $9.05M | $3.78M | $6.63M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-290M | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $8.74T | $9.88T | $8.76M | $8.77M | $20.3M |
| Net change in cash | $808.3B | $2.38T | -$-2.02M | -$-9.12M | $12.1M |
| Cash at end of period | $4.31T | $3.5T | $1.12M | $3.15M | $12.3M |
| Operating cash flow | -$-7.81T | -$-7.5T | -$-10.78M | -$-17.89M | -$-8.24M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-7.81T | -$-7.5T | -$-10.78M | -$-17.89M | -$-8.24M |
Line items
Line items
Line items
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
- CEO
- D. Lynn Kirkpatrick
- Employees
- 10
- Beta
- 0.90
Explore
Frequently asked questions
What is the intrinsic value of Ensysce Biosciences, Inc. (ENSC)?
InvestorsCraft does not currently publish an intrinsic value for ENSC. How the IC value is calculated.
Is ENSC undervalued?
InvestorsCraft does not publish an undervaluation signal for ENSC at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.